Crizotinib-resistant crizotinib-resistance patients with MET-amplified brain metastases from lung cancer

*For medical professional reading reference only

The treatment journey of a patient with EGFR mutation

EGFR mutation is the most common type of mutation in Chinese non-small cell lung cancer (NSCLC) patients, present in about half of the patients

Therefore, the patient was switched to the fourth-line treatment of osimertinib + savatinib

The treatment process of this case once again confirms the long-term survival benefit of osimertinib + sevolitinib for MET-amplified NSCLC patients with EGFR-TKI resistance, and switching to sevor for crizotinib resistance Tini provides a reference

MET amplification is an important mechanism of acquired resistance to EGFR-TKIs

In the above case, the patient received first- and third-generation EGFR-TKI treatment successively.

Combined with clinical research data and the efficacy of real-world cases, it can be seen that MET-TKI has great potential for the treatment of MET amplification resistance
.

In the future, with the continuous enrichment of evidence-based medical evidence, MET-TKI is expected to benefit more lung cancer patients
.

Brief Introduction of Case Review Expert Prof.
Ren Xiubao

Director of the Department of Biotherapy Oncology, Tianjin Cancer Hospital, Doctoral Supervisor, Chief Physician, Doctor of Medicine

Director of Biotechnology Research Office, Tianjin Cancer Institute

Vice-Chairman and Secretary-General of the Professional Committee for Clinical Application of Medical Biotechnology, China Medical Biotechnology Association

Member of the Standing Committee of the Cancer Biotherapy Professional Committee of the Chinese Anti-Cancer Association

Director of Tianjin Anti-Cancer Association

Director of the 6th Council of the Chinese Society for Immunology

Member of the 2nd China Expert Group on Human Genetic Resources Management

Member of Standing Committee of Lung Cancer Professional Committee of Tianjin Anti-Cancer Association

Member of the Standing Committee of the Professional Committee of Cancer Rehabilitation and Palliative Care of Tianjin Anti-Cancer Association

Member of Tissue Engineering Professional Committee of Tianjin Biomedical Engineering Society

Deputy Director of Tianjin Lung Cancer Diagnosis and Treatment Center

Member of the Oncology Credit Evaluation Committee of Tianjin Medical University

Cases provide expert briefings

Professor Zhang Weihong

Department of Biotherapy, Tianjin Medical University Cancer Hospital

Vice Chairman of Tianjin Anti-Cancer Association Melanoma Professional Committee

Member of the Clinical Application Professional Committee of China Medical Biotechnology Association

Member of the Youth Committee of Cancer Chemotherapy Professional of China Medical Education Association

Danna-FarberCancer Institute

Moffitt Cancer Center

Reference: [1].
Pasquini G, Giaccone G.
C-MET inhibitors for advanced non-small cell lung cancer[J].
Expert Opin Investig Drugs.
2018;27(4):363-375.
[2].
Bean J, Brennan C, Shih JY, et al.
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J].
Proc Natl Acad Sci US A.
2007;104(52):20932 -7.
[3].
Papadimitrakopoulou V, et al.
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.
2018 ESMO Abstract LBA51.
[4].
Ramalingam SS, Cheng Y, Zhou C, et al.
Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study.
2018 ESMO Congress.
Abstract LBA50.
[5].
Leonetti A, Sharma S, Minari R, et al.
Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer.
Br J Cancer.
2019;121(9):725-737.
[6].
Lecia V Sequist, Ji-Youn Han, et al.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small- cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J].
Lancet Oncol.
2020;21(3):373-386.
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform